PROJECTS MEETINGS NETWORKS

CZECHIA’S REFERENCE CENTER CONTACT INFORMATION

Name:
Masaryk University - CEITEC and University Hospital Brno
Address:
Kamenice 5, building A35, 625 00 Brno, Czech Republic and Cernopolni 9, 613 00 Brno, Czech Republic.
Contact 01:
Sarka Pospisilova
Email:
sarka.pospisilova@ceitec.muni.cz
Phone:
+420 532234622/+420 549497917
Contact 02:
Jitka Malcikova
Email:
jitka.malcikova@gmail.com
Phone:
+420 532234396/+420 549497948
VISIT WEBSITE

DENMARK’S REFERENCE CENTER CONTACT INFORMATION

Name:
Rigshospitalet, Leukemia Laboratory
Address:
Copenhagen University Hospital, Dpt of Hematology, Building 4042, Blegdamsvej 9, 2100 Copenhagen Ø, Denmark.
Contact 01:
Carsten Utoft Niemann
Email:
carsten.utoft.niemann@regionh.dk
Phone:
+45 35457830
Contact 02:
Lone Bredo Pedersen
Email:
Lone.Bredo.Pedersen@regionh.dk
Phone:
+45 35453826
VISIT WEBSITE

FRANCE’S REFERENCE CENTER CONTACT INFORMATION

Name:
Molecular Hematology Unit, Hôpital Pitié-Salpêtrière
Address:
Division of Hematology, Dpt of Laboratory Medicine & Pathology, 47-83 Boulevard de l'Hôpital, 75013, Paris, France.
Contact 01:
Fred Davi
Email:
frederic.davi@aphp.fr
Phone:
+33 142160193
Contact 02:
Marine Armand
Email:
marine.armand@aphp.fr
Phone:
33 142160191
VISIT WEBSITE

GERMANY’S REFERENCE CENTER CONTACT INFORMATION

Name:
CLL laboratory - Department of Internal Medicine III - Ulm University
Address:
Albert-Einstein-Allee 23 - 89081 Ulm - GermanyAlbert Einstein Allee 23, 89081, Ulm, Germany.
Contact 01:
Stephan Stilgenbauer
Email:
stephan.stilgenbauer@uniklinik-ulm.de
Phone:
+49 73150045521
Contact 02:
Eugen Tausch
Email:
eugen.tausch@uniklinik-ulm.de
Phone:
+49 73150045729
VISIT WEBSITE

GREECE’S REFERENCE CENTER CONTACT INFORMATION

Name:
Institute of Applied Biosciences
Address:
Center for Research and Technology Hellas, 6th Km Charilaou-Thermis, 57001, Thessaloniki, Greece
Contact 01:
Kostas Stamatopoulos
Email:
kostas.stamatopoulos@gmail.com
Phone:
+30 2310498271
Contact 02:
Anastasia Hadzidimitriou
Email:
anastasiaxtz@gmail.com
Phone:
+30 2310498474
VISIT WEBSITE

ITALY’S REFERENCE CENTER CONTACT INFORMATION

Name:
Division of Hematology, University of Eastern Piedmont
Address:
Division of Hematology, Dpt of Translational Medicine, University of Eastern Piedmont, Via Solaroli 17, 28100 Novara, Italy
Contact 01:
Gianluca Gaidano
Email:
gianluca.gaidano@med.uniupo.it
Phone:
+39 0321 660655
Contact 02:
Clara Deambrogi
Email:
clara.deambrogi@med.uniupo.it
Phone:
+3903213732194
VISIT WEBSITE

SPAIN’S REFERENCE CENTER CONTACT INFORMATION

Name:
Hospital Universitario de Salamanca (CAUSA-IBSAL)
Address:
Servicio de Hematología, Lab. de Biología Molecular y HLA, Paseo de San Vicente 58-182, 37007, Salamanca, Spain
Contact 01:
Marcos González Díaz
Email:
margondi@usal.es
Phone:
+34 923291100 Ext 55629/55765
Contact 02:
Miguel Alcoceba Sánchez
Email:
migalcoceba@gmail.com
Phone:
+34 923291100 Ext 55765/55629
VISIT WEBSITE

SWEDEN AND NORDIC COUNTRIES’S REFERENCE CENTER CONTACT INFORMATION

Name:
Clinical Genetics Uppsala
Address:
Clinical Genetics, Uppsala University Hospital, Rudbeck laboratory,bldg C11, S-751 85 Uppsala, Sweden
Contact 01:
Lesley-Ann Sutton
Email:
lesley-ann.sutton@ki.se
Phone:
+46 184714867
Contact 02:
Richard Rosenquist
Email:
richard.rosenquist@ki.se
Phone:
+46 706253384
VISIT WEBSITE

SWITZERLAND’S REFERENCE CENTER CONTACT INFORMATION

Name:
Oncology Institute of Southern Switzerland
Address:
Via Ospedale, 6500 Bellinzona, Switzerland
Contact 01:
Davide Rossi
Email:
davide.rossi@eoc.ch
Phone:
+41 918118665
Contact 02:
Renzo Lucchini
Email:
Renzo.lucchini@eoc.ch
Phone:
+41 918111743
VISIT WEBSITE

THE NETHERLANDS’S REFERENCE CENTER CONTACT INFORMATION

Name:
Academic Medical Center Amsterdam
Address:
Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
Contact 01:
Arnon Kater
Email:
a.p.kater@amc.nl
Phone:
+31 205665785
Contact 02:
Clemens Mellink
Email:
c.h.mellink@amc.uva.nl
Phone:
+31 2056665169
VISIT WEBSITE

UNITED KINGDOM’S REFERENCE CENTER CONTACT INFORMATION

Name:
Belfast City Hospital, Molecular Haemotology
Address:
51 Lisburn Road, BT9 7AB, United Kingdom
Contact 01:
Mark Catherwood
Email:
Mark.Catherwood@belfasttrust.hscni.net
Phone:
+44 (0)28 95048138
Contact 02:
David Gonzalez de Castro
Email:
D.GonzalezdeCastro@qub.ac.uk
Phone:
+44 (0)28 9097292
VISIT WEBSITE

CZECHIA’S CERTIFYING CENTER CONTACT INFORMATION

Name:
Masaryk University - CEITEC and University Hospital Brno
Address:
Kamenice 5, building A35, 625 00 Brno, Czech Republic and Cernopolni 9, 613 00 Brno, Czech Republic.
Contact 01:
Sarka Pospisilova
Email:
sarka.pospisilova@ceitec.muni.cz
Phone:
+420 532234622/+420 549497917
Contact 02:
Jitka Malcikova
Email:
jitka.malcikova@gmail.com
Phone:
+420 532234396/+420 549497948
VISIT WEBSITE
CERTIFIED CENTERS+
  • ARGENTINA
  • AUSTRALIA
  • AUSTRIA
  • BELGIUM
  • BRAZIL
  • BULGARIA
  • CANADA
  • CHINA
  • CROATIA
  • CYPRUS
  • CZECH REPUBLIC
  • DENMARK
  • ESTONIA
  • FINLAND
  • FRANCE
  • GERMANY
  • GREECE
  • HUNGARY
  • INDIA
  • IRELAND
  • ISRAEL
  • ITALY
  • JORDAN
  • LATVIA
  • LITHUANIA
  • MACEDONIA
  • MEXICO
  • NETHERLANDS
  • NORWAY
  • POLAND
  • PORTUGAL
  • QATAR
  • ROMANIA
  • RUSSIA
  • SLOVAKIA
  • SLOVENIA
  • SOUTH AFRICA
  • SPAIN
  • STATE OF PALESTINE
  • SWEDEN
  • SWITZERLAND
  • TURKEY
  • THE UNITED KINGDOM
BACKGROUND+

In chronic lymphocytic leukemia (CLL), TP53 gene aberrations due to chromosome 17p deletion ⌊del (17p)⌋ and/or TP53 gene mutation are associated with adverse prognosis and poor response to chemo (immuno) therapeutic regimens. Deletion and/or mutation of the TP53 gene occur on average in 10-15% of untreated CLL patients, and the incidence rises to 40-50% in fludarabine-refractory cases. It has been shown that TP53 mutations in the absence of del (17p) occur in a sizeable proportion of CLL patients (~5% in first line treatment situation) and are also associated with significantly worse outcome.

The European Research Initiative on CLL (ERIC) has a longstanding interest in the standardization and harmonization of diagnostic techniques for such aberrations including FISH ⌊to detect del (17p)⌋ and molecular (to detect TP53 mutations) analyses, providing guidelines to the international scientific community (Pospisilova et al, Leukemia 2012).

Until recently, no effective treatments were available for these patients, as chemo (immuno) therapeutic regimens could only achieve limited and short-lasting responses (e.g. PFS approx. 12 months with FCR in the 1st line setting) with a dismal prognosis despite additional lines of treatments, with the allogeneic transplant being the only potentially curative approach.

Recently, however, the outcome of CLL patients with del (17p) and/or TP53 gene mutation has improved dramatically by treatment with novel, non-chemotherapeutic agents such as the signaling inhibitors ibrutinib and idelalisib (the latter in combination with Rituximab) and the BCL-2 inhibitor venetoclax, which have been approved by the FDA and the EMA for this group of patients. That said, long term follow-up is required before drawing definitive conclusions regarding the extent to which TP53 gene disruption may maintain a prognostic role also with these novel agents.

Availability of these new drugs creates the need for practicing hematologists to carefully screen for del (17p) and TP53 gene mutations in all cases before the implementation of both first and subsequent lines of treatment in order to select the most appropriate treatment, while avoiding potentially ineffective regimens and unnecessary toxicity. This is especially timely given that the appropriate diagnostic techniques are currently not available or utilized in all centers treating CLL patients; furthermore, with few exceptions, quality control procedures are not in place.

AIMS+

OUR AIMS

ERIC aims to promote and/or advance the assessment of TP53 gene aberrations for diagnostic purposes by educating the hematological community about; 1) the need for performing such tests in all cases that require therapy, in both first and subsequent lines of treatment; 2) the quality of the appropriate techniques to be utilized by diagnostic laboratories to ensure reliable and comparable results across different institutions in Europe and elsewhere.

Ultimately, this will improve optimal patient care and will increase the availability of relevant tests, allowing clinical study groups, as well as the pharmaceutical industry, to focus on these particularly difficult-to-treat CLL patients and channel them to clinical trials aimed at further improving long-term outcomes.

The project is addressed to all scientific personnel working in laboratories performing diagnostics for patients with CLL including: those who have never performed the analyses in the past, those who have recently introduced novel diagnostics and need reassurance on the correctness of the procedure, and those already experienced in their use who need official certification of quality control for applied methodologies. It is also aims to increase physicians’ awareness of the need to test all CLL patients requiring therapy in order to select the most appropriate treatment for each case.

WORKING PLAN AND SPECIFIC OBJECTIVES
The project will accomplish its goals using the following approaches:

EDUCATIONAL EVENTS
1ST ERIC WORKSHOP ON TP53 ANALYSIS IN CLL
A hands-on workshop was held from 1-3 October, 2015 in Brno (Czech Republic) in which participants were introduced to both the scientific rationale for performing these diagnostic procedures and the basic principles of the relevant methodologies. This was the first ERIC TP53 Workshop on TP53 Analysis in Chronic Lymphocytic Leukemia. Its main goal was to address important biological, methodical and clinical questions relating to the role of TP53 abnormalities in Chronic Lymphocytic Leukemia. More than 130 participants from various countries were given the opportunity to learn, share ideas and discuss the current state of knowledge and future perspectives in a friendly atmosphere during the scientific sessions and social events. During the workshop, participants had a chance to explore the actual practical work, from the sample collection to the drafting of the final clinical report. This activity could also be extended to clinical study groups and industry partners to improve both the standardization of the assay and the interpretation of the results within investigator – or company-driven clinical trials.

2ND ERIC WORKSHOP ON TP53 ANALYSIS IN CLL
A hands-on workshop was held from 7-8 November, 2017 in Stresa (Italy). At this Workshop there was a special emphasis placed on both theoretical and practical aspects of p53 inactivation in leukemic cells, introduction of TP53 mutational analysis into the clinical diagnostics and data interpretation. There was also Panel discussions and an interactive workshop focusing on the practical aspects of TP53 analysis. The aim of the workshop was to attract top experts in the field to share their knowledge and experience. This event was organized by the Certifying Centre in Brno, Czech Republic who also organized the first TP53 Workshop.

ESTABLISHMENT AND EXPANSION OF THE TP53 NETWORK
A network of reference laboratories has been established and is providing ongoing supervision and advice to individual laboratories that need to set-up, improve or consolidate the diagnostic techniques for the assessment of TP53 gene aberrations in their laboratories. The current Network has grown and now consists of three Certifying Centers (Czech Republic, Germany and Sweden and Nordic Countries), for internal certification of the requesting labs, and eleven Reference Centers (originally eight), one for each participating country or region (Czech Republic, Denmark, France, Germany, Greece, Italy, Spain, Sweden and Nordic Countries, Switzerland, The Netherlands, United Kingdom), that will coordinate the work and ensure the overall quality of the network. The different centers will either help to set up the diagnostic procedures or directly perform the analyses for requesting laboratories while the latter are in the process of implementing them in their own facilities. ERIC is now a truly global network but aims to further expand this network in the future.

CERTIFICATION OF TP53 MUTATIONAL ANALYSIS
The certification process can be summarized as follows:

PHASE 1: COMPLETION OF PARTICIPATION FORM
Interested laboratories should complete the participation form in order to be eligible for the next certification round. The participation form can be found by clicking here

PHASE 2: LABORATORY AND BIOINFORMATICS ANALYSIS
Once the list of participating laboratories has been defined, these laboratories will be asked to confirm their shipping details and confirm that they still wish to participate.

The certifying centre will prepare the quality control material – genomic DNA from 5 CLL cases of diverse TP53 status – and ship this to the corresponding laboratories.

Laboratories will be informed as to when they should receive their samples and will be provided with instructions (via email) as to how to proceed with the certification process. The laboratories will be provided with the samples and all the necessary guidelines in order to carry out the analysis. The analysis will be completed through the submission of an online personalized form which must be sent within 3 months.

PHASE 3: EVALUATION & DECISION
The results will be analysed by the Certifying Centre in terms of both the analysis per se and the interpretation of the findings. Successful laboratories will be provided with a certificate (either Standard or Good Laboratory Practice) and a letter summarizing their performance and unsuccessful laboratories will be asked to reapply at the next round and be provided with necessary guidance.

SUMMARY: CERTIFICATION ROUNDS
Eight rounds of TP53 Certification have already been completed and the next round will be announced soon. The participation survey remains active for the whole year for those labs interested to participate in the next round. Should your lab be interested, then please ensure that you complete and send the Participation Form which can be found here

ONLINE WEB TOOLS
The following online web tools have been created and are available in order to provide laboratories with guidance and assistance to achieve reliable and comparable results for TP53 mutational analysis:

ONLINE HELP DESK
The online help desk has been specifically set up for laboratories facing any difficulties during the analysis. It provides methodological as well as interpretation consultation.

FREE SOFTWARE OF SANGER ANALYSIS DATA (GLASS)
This software helps laboratories with the analysis of Sanger Sequencing data.

GUIDANCE TOOLS FOR CERTIFICATION
TP53 CERTIFICATION REQUIREMENTS
A brief checklist summarizing what is needed to be successful in the certification round.

THE TP53 ANALYSIS TEMPLATE REPORT FORM
This template serves as an example in the correct and comprehensive result report that should be provided to the physicians.

A MANUAL FOR TP53 ANALYSIS
This manual contains concise information on the TP53 mutational analysis process from sampling to data interpretation.

STRUCTURE+
REFERENCE CENTRES
  • CZECHIA
  • DENMARK
  • FRANCE
  • GERMANY
  • GREECE
  • ITALY
  • SPAIN
  • SWEDEN AND NORDIC COUNTRIES
  • SWITZERLAND
  • THE NETHERLANDS
  • UNITED KINGDOM
CERTIFYING CENTER
  • CZECHIA
PARTICIPATION FORM+
TP53 NETWORK PARTICIPATION FORM
Full Name:
Institution: (Name that will appear on the diploma
Department:
Address to send the samples:
City:
Postal code:
Country:
E-mail:
Additional e-mail:
Phone:
Additional phone:
If your country doesn’t belong to the European Union, it is compulsory to provide the VAT/TAX number of your laboratory (HST, Federal Tax Number, ID…)
Tax number:
SUBMIT APPLICATION
TP53 NETWORK PARTICIPATION FORM
Full Name:
Institution: (Name that will appear on the diploma
Department:
Address to send the samples:
City:
Postal code:
Country:
E-mail:
Additional e-mail:
Phone:
Additional phone:
If your country doesn’t belong to the European Union, it is compulsory to provide the VAT/TAX number of your laboratory (HST, Federal Tax Number, ID…)
Tax number:
SUBMIT APPLICATION
HELP DESK+
TP53 NETWORK HELP DESK
Please remember to attach the sequence at the end of the form.
Sequences from both forward and reverse strand should be included.
Full Name:
Institution / Clinic:
City:
Postal code:
Country:
Case ID:
E-mail:
Phone:
Molecule type:
Method used:
If other method, please specify:
Enter your question:
I agree to have my case included in the ERIC database of problematic cases
Please upload your file(s) here (limit of 5 documents). Please attach the sequence in any of the supported formats.
Department:
Institution Address:
City:
Postal code:
Country:
E-mail:
Phone:
I agree to have my case included in the ERIC database of problematic cases
SUBMIT APPLICATION
TP53 NETWORK HELP DESK
Please remember to attach the sequence at the end of the form.
Sequences from both forward and reverse strand should be included.
Full Name:
Institution / Clinic:
City:
Postal code:
Country:
Case ID:
E-mail:
Phone:
Molecule type:
Method used:
If other method, please specify:
Enter your question:
I agree to have my case included in the ERIC database of problematic cases
Please upload your file(s) here (limit of 5 documents). Please attach the sequence in any of the supported formats.(TXT, PDF, DOC)
Department:
Institution Address:
City:
Postal code:
Country:
E-mail:
Phone:
I agree to have my case included in the ERIC database of problematic cases
SUBMIT APPLICATION
FAQ+

How long does the lab have to analyse the samples?
Normally two months. Deadlines will be outlined.

How long for results to be sent after submitting the results?
Deadline will be provided.

How should the results be submitted?
Via an online personalised form that you will be sent.

Who should I contact if I need assistance?
Please email the ERIC Office.

How long is the certification valid for?
Three years.

How can I renew my certification?
Renewals are made by GenQA and UK NEQAS LI. You can find all the information here.

How can I certify my lab?
Please complete the Participation Form

How long does it take to receive participation confirmation?
You will be contacted via email. This may take a few weeks.

Who decides whether my lab can participate?
The certifying centre in charge of the Round.

Is Certification free?
Yes it is. All courier costs are covered by ERIC.

How many certification rounds are there per year and when may I register for the next round?
Normally one per year. Participation form is open all year round.

How long is the certification valid for?
Three years.

How can I renew my certification?
Renewals are made by GenQA and UK NEQAS LI. You can find all the information here.

How can I request a duplicate certificate?
Please contact the ERIC Office.

Which type of certification exists?
Standard and GLP (Good Laboratory Practice).

How many times can my lab reapply if unsuccessful?
There is no limit.

How can I find out more about certified labs?
Please click on the Certified centres and Certification Round sections on the website.

When will the samples be sent?
You will be informed via email.

How many samples will be sent?
You will receive five samples.

Which type of samples will be sent?
DNA samples.

Which techniques are being certified?
Next Generation Sequencing and Sanger Sequencing.

Can my lab certify for more than one technique?
Yes.

ARGENTINA

Buenos Aires, National Academy of Medicine (March 2022)

AUSTRALIA

East Melbourne. Peter MacCallum Cancer Centre (February 2019)

Bedford Park, SA Pathology (June 2016)

Bedford Park, GNOMIX Pty Ltd (February 2021)

AUSTRIA

Innsbruck, Institute of Human Genetics (March 2022)

Innsbruck, Med. und Chem. Labordiagnostik, Universitätsklinik Innsbruck (February 2019)

Linz. Elisabethinen Hospital Linz (June 2016)

Vienna, AKH Vienna (February 2019)

Vienna, Clinical Institute of Laboratory Medicine (January 2015)

Vienna, Medical University of Vienna (February 2018)

BELGIUM

Brugge, AZ Sint-Jan Brugge-Oostende AV (March 2024)

Brussels, Hospital Erasme (February 2018)

Edegem, University Hospital Antwerp, UZA (February 2021)

Gent, AZ Sint-Lucas (February 2019)

Gent, Ghent University Hospital (June 2018)

Leuven, UZ Leuven (February 2018)

Liege, CHU Liège (February 2016, September 2019)

Roeselare, AZ Delta Hospital (February 2019)

BRAZIL

Rio de Janeiro, Instituto Nacional de Câncer-INCA (February 2018)

Sao Paulo, University of Sao Paulo (January 2017)

Sao Paulo, Fleury (March 2023)

BULGARIA

Sofia, Genome Diagnostics Laboratory (March 2024)

CANADA

Montreal, Jewish General Hospital (February 2021)

Ontario, Health Sciences North (April 2019)

CHINA

Beijing, Peking University People’s Hospital (April 2020)

Jiangsu, The First Affiliated Hospital of Soochow University (March 2024)

Nanjing, The First Affiliated Hospital of Nanjing Medical University (September 2021)

CROATIA

Zagreb, University Hospital Dubrava (March 2024)

CYPRUS

Nicosia, Karaiskakio Foundation (January 2017)

CZECH REPUBLIC

Brno, University Hospital Brno – 2 methods (February 2018)

Hradec Kralove, Faculty Hospital (January 2017)

Novy Jicin, Laboratore AGEL a.s. (June 2016)

Olomouc, University Hospital Olomouc (June 2016)

Prague, GHC Genetics (March 2022)

Prague, General Teaching Hospital (February 2021)

DENMARK

Aalborg, Aalborg University Hospital (February 2019)

Copenhagen, Rigshospitalet (June 2018)

Herlev, Herlev Hospital (February 2021)

Odense, Odense University Hospital (February 2018)

Roskilde, Zealand University Hospital (February 2021)

ESTONIA

Tartu, Tartu University Hospital United Laboratories (March 2024)

FINLAND

Oulu, Nordlab (February 2019)

Turku, Hospital District of Southwest Finland (February 2018)

FRANCE

Basse Normandie, CHU Caen (February 2021)

Besancon, EFSBFC (March 2022)

Bobigny, Hôpital Avicenne – 2 methods (September 2019)

Clermont-Ferrand, CHU Clermont-Ferrand CHU Estaing (January 2015)

Créteil, Hôpital Henri Mondo (January 2015 )

Le Chesnay, Centre Hospitalier de Versailles (April 2020)

Montpellier, CHU Montpellier – Hopital St Eloi (June 2016)

Nantes, CHU de Nantes – Hôtel-Dieu (April 2020)

Paris, Hôpital Universitaire Pitié Salpêtrière (February 2019)

Pessac, CHU Bordeaux (February 2018)

Reims, L´Hôpital Robert Debré – CHU de Reims – 2 methods (January 2017)

Strasbourg, Strasbourg Hospital (September 2019)

Toulouse, CHU de Toulouse (January 2015)

Toulouse, Institut Universitaire du Cancer de Toulouse (September 2019)

Vandoeuvre-les-Nancy, CHU Nancy Hôpitaux de Brabois (January 2017)

GERMANY

Cologne, Labor Dr. Wisplinghoff (February 2018)

Cologne, MVZ Labor Dr. Quade & Kollegen (March 2024)

Cologne, Uniklinik Köln (February 2021)

Dortmund, MVZ Dr Eberhard & Partner Dortmund (September 2023)

Dresden, AgenDix GmbH (March 2024)

Göttingen, Klinik für Hämatologie und Onkologie (September 2019)

Hannover, Hannover Medical School (June 2018)

Mannheim, IHO GmbH (2017)

Mannheim, Labor für Haematologie Mannheim -HaeMa- (March 2024)

Munich, MLL Munich Leukemia Laboratory  – 2 methods (February 2019)

Rostock, MVZ für Humangenetik und Molekularpathologie GmbH (March 2024)

Ulm, Ulm University (February 2019)

GREECE

Athens, National and Kapodistrian University of Athens (February 2016)

Athens, Center of Molecular Diagnostics in Hematology (March 2024)

Thessaloniki, INAB-CERTH (June 2018)

Thessaloniki, Papanikolaou Hospital (January 2015)

Thessaloniki, Institute of Applied Biosciences (March 2024)

HUNGARY

Budapest, Central Hospital of Southern Pest (Sept 2021)

Budapest, Semmelweis University (June 2018)

Debrecen, University of Debrecen (Sept 2021)

INDIA

Mumbai, Tata Memorial Centre (April 2019)

IRELAND

Dublin, St James´s Hospital (January 2017)

ISRAEL

Haifa, Carmel Medical Center (September 2021)

Haifa, Rambam Medical Centre (January 2017)

Haifa, The Bnai Zion Medical Center (February 2019)

Ramat Gan, Sheba Medical Center (April 2020)

Tel-Aviv, Tel-Aviv Sourasky Medical Centre (January 2017)

ITALY

Ancona, AOU Ospedali Riuniti (March 2022)

Ascoli Piceno, Ospedale “C. e G. Mazzoni” ASUR 5 (February 2019)

Aviano, Centro di Riferimento Oncologico di Aviano (April 2020)

Bari, IRCCS Istituto Tumori “Giovanni Paolo II” (June 2018)

Bari, University of Bari (June 2018)

Bergamo, ASST Papa Giovanni XXIII (April 2020)

Bologna, University of Bologna (January 2015)

Brescia, Spedali Civili Di Brescia (June 2018)

Ferrara, University of Ferrara (June 2016)

Milano, ASST Great Metropolitan Niguarda (January 2015)

Milano, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano (June 2018)

Milano, Ospedale San Raffaele (February 2019)

Milano, A.O. Annunziata di Cosenza (December 2018)

Modena, Azienda Ospedaliero – Universitaria Policlinico di Modena (March 2024)

Novara, University of Eastern Piedmont (September 2021)

Nuoro, San Francisco Hospital – 2 methods (February 2021)

Padova, Istituto Oncologico Veneto IRCCS (February 2019)

Palermo, AOR Villa Sofia Cervello (June 2018)

Pavia, Fondazione IRCCS Policlinico San Matteo (June 2018)

Perugia, University of Perugia (June 2018)

Pescara, University of Chieti-Pescara (February 2019)

Piacenza, Azienda Usl Piacenza Ospedale G. da Saliceto (June 2018)

Piedmont, University of Eastern Piedmont (January 2015)

Reggio Emilia, Laboratorio di Genetica (June 2018)

Rome, Policlinico Universitario Agostino Gemelli (April 2020)

Rome, Sapienza University of Rome (June 2018)

Torino, SC Anatomia e Istologia Patologica 1U (June 2016)

Vicenza, Azienda Ulss8 Berica (March 2024)

Vicenza, San Bortolo Hospital (February 2019)

JORDAN

Amman, King Hussein Cancer Center (February 2021)

LATVIA

Riga, Riga Stradins University (March 2024)

LITHUANIA

Kaunas, Hospital of Lithuanian University of Health Sciences (March 2024)

Vilnius, Center for Innovative Medicine (February 2019)

MACEDONIA

Skopje, UKIM – Faculty of Pharmacy (February 2016)

MEXICO

Ciudad de Mexico, Genos Médica (March 2024)

NETHERLANDS

Amsterdam, Academic Medical Center, University of Amsterdam (February 2016)

Amsterdam, Sanquins Diagnostics (April 2020)

Groningen, University Medical Centre Groningen (March 2024)

Maastricht, Maastricht University Hospital (June 2016)

Nijmegen, Radboud University Medical Centre Nijmegen (June 2018)

Rotterdam, Erasmus University Medical Centre (January 2017)

Utrecht, UMC Utrecht – 2 departments (March 2024)

NORWAY

Oslo, Oslo Universitetssykehus, Radiumhospitalet (April 2019)

POLAND

Biała Podlaska, Provincial Specialist Hospital In Biała Podlaska (March 2024)

Brzozów, Szpital Specjalistyczny w Brzozowie POO im. Ks. B. Markiewicza (September 2019)

Bydgoszcz, Nicolaus Copernicus University (September 2019)

Gdansk, Medical University of Gdansk (February 2019)

Kielce, Holycross Cancer Center (February 2021)

Krakow, Oncogene Diagnostics Sp z o.o. (February 2021)

Krakow, University Hospital in Krakow (February 2019)

Łódź, Wojewódzkie Wielospecialistyczne Centrum Onkoloii I Traumatologii (March 2023)

Lublin, Medical University of Lublin (March 2024)

Poznan, Zakład Diagnostyki Medycznej Sp. z o.o. (February 2019) 

Poznan, Laboratorium Diagnostyki Hematologicznej (September 2019)

Rzeszow, Uniwersytecki Szpital Kliniczny w Rzeszowie (March 2023)

Warsaw, Institute of Hematology and Blood Transfusion (March 2023)

Warsaw, Medical University of Warsaw – 2 methods – (February 2019)

Warsaw, The Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology (September 2019)

Wroclaw, Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu (April 2020)

PORTUGAL

Coimbra, Centro Hospitalar E Universitário de Coimbra (June 2018)

Lisbon, GenoMed – Diagnósticos de Medicina Molecular, SA (June 2018)

Lisbon, Portuguese Institute of Oncology of Lisbon (March 2024)

Porto, Hospital de São João (January 2017)

Porto, Instituto Português de Oncologia IPO-Port (February 2019)

QATAR

Doha, Hamad Medical Corporation (March 2024)

ROMANIA

Bucharest, University Emergency Hospital Bucharest (March 2024)

RUSSIA

Kirov, Institution Kirov Research Institute of Hematology and Blood Transfusion (July 2024)

Moscow, National Research Center for Hematology (February 2016)

Saint-Petersburg, Almazov North-West Federal Research Center (June 2016)

SLOVAKIA

Bratislava, National Cancer Institute (February 2016)

SLOVENIA

Ljubljana, University Medical Centre Ljubljana (September 2019)

SOUTH AFRICA

Centurion, Ampath Laboratories (March 2024)

Pretoria, Oncolab Diagnostics (September 2021)

SPAIN

Barcelona, Hospital Clínic i Provincial de Barcelona (March 2024)

Barcelona, Hospital Germans Trias i Pujol Badalona (January 2017)

Barcelona, Hospital del Mar (March 2024)

Barcelona, Hospital de la Santa Creu i Sant Pau (September 2021)

Barcelona, Hospital Vall d’Hebron (March 2024)

Canarias, Hospital Universitario de Gran Canaria Dr. Negrín (February 2021)

Madrid, Hospital Clínico San Carlos (January 2017)

Madrid, Hospital Gregorio Marañón (January 2017)

Madrid, Hospital Universitario 12 de Octubre (February 2019)

Madrid, Hospital Universitario Fundación Jiménez Díaz (January 2017)

Madrid, Hospital Universitario Puerta de Hierro (September 2019)

Madrid, NIMGenetics (April 2020)

Madrid, Secugen S. L. (February 2019)

Madrid, Synlab  (February 2021)

Murcia, Centro Regional de Hemodonación (February 2021)

Oviedo, Hospital Universitario Central de Asturias (January 2017)

Pamplona, Complejo Hospitalario de Navarra (January 2017)

Pamplona, CIMA Universidad de Navarra (March 2024)

Salamanca, CIDEGEN (February 2021)

Salamanca, Hospital Universitario de Salamanca (March 2022)

San Sebastián, Donostia University Hospital (February 2021)

Santander, Genetracer Biotech (February 2019)

Valencia, Hospital Arnau de Vilanova (March 2022)

Valencia, Hospital Clínico Universitario INCLIVA – 2 methods – (March 2023)

Valencia, Hospital Universitario La Fe (Feb 2018)

STATE OF PALESTINE

Jerusalem, Augusta Victoria Hospital (April 2020)

SWEDEN

Göteborg, Sahlgrenska University Hospital: 2 methods (February 2018)

Huddinge, Karolinska University Hospital Huddinge (February 2019)

Solna, Karolinska University Hospital Solna (January 2017)

Umeå, Medical and Clinical Genetics, Umeå Universitet (February 2019)

Uppsala, Uppsala Academic Hospital – 2 methods (January 2017)

SWITZERLAND

Basel, University Hospital Basel (January 2017)

Bellinzona, IOSI – Oncology Institute of Southern Switzerland (February 2016)

Bern, University Hospital Inselspital Bern (June 2018)

Bioggio, Laboratorio Synlab Ticino (April 2020)

Lausanne, Chuv (June 2016)

Lausanne, Unilabs (January 2017)

St Gallen, Kantonsspital St Gallen (February 2018)

Zürich, Universitätsspital Zürich, USZ (April 2020)

Zürich, University Children’s Hospital Zurich, (April 2020)

TURKEY

Ankara, INTERGEN (February 2021)

Istanbul, Koc University Hospital (September 2021)

THE UNITED KINGDOM

Aberdeen, NHS Grampian (February 2021)

Belfast, Belfast City Hospital (February 2016)

Birmingham, Birmingham Women’s Hospital (January 2015)

Bournemouth, Royal Bournemouth Hospital (February 2019)

Bristol, Southmead Hospital Bristol – North Bristol NHS Trust (April 2020)

Cardiff, All Wales Medical Genomics Laboratory (February 2021)

Edinburgh, NHS Lothian (June 2018)

Leicester, University of Leicester (January 2015)

Liverpool, Royal Liverpool University Hospital (January 2015, June 2018, Feb 2021)

London, The Rayne Institute London – King’s College (April 2020)

Manchester, Manchester University NHS Foundation Trust (February 2021)

Oxford, John Radcliffe Hospital (February 2018)

Oxford, Oxford Molecular Diagnostic Centre, NHS Trust (January 2015)

Salisbury, Salisbury NHS Foundation Trust (April 2020)

Salisbury, Wessex Regional Genetics Laboratory (January 2017)

Southampton, University of Southampton (April 2020)

Sutton, The Royal Marsden NHS Foundation Trust – 2 methods (June 2018)

Whitechapel, Barts Health NHS Trust (April 2020)

How long does the lab have to analyse the samples?
Normally two months. Deadlines will be outlined.

How long for results to be sent after submitting the results?
Deadline will be provided.

How should the results be submitted?
Via an online personalised form that you will be sent.

Who should I contact if I need assistance?
Please email the ERIC Office.

How long is the certification valid for?
Three years.

How can I renew my certification?
Renewals are made by GenQA and UK NEQAS LI. You can find all the information here.

How can I certify my lab?
Please complete the Participation Form

How long does it take to receive participation confirmation?
You will be contacted via email. This may take a few weeks.

Who decides whether my lab can participate?
The certifying centre in charge of the Round.

Is Certification free?
Yes it is. All courier costs are covered by ERIC.

How many certification rounds are there per year and when may I register for the next round?
Normally one per year. Participation form is open all year round.

How long is the certification valid for?
Three years.

How can I renew my certification?
Renewals are made by GenQA and UK NEQAS LI. You can find all the information here.

How can I request a duplicate certificate?
Please contact the ERIC Office.

Which type of certification exists?
Standard and GLP (Good Laboratory Practice).

How many times can my lab reapply if unsuccessful?
There is no limit.

How can I find out more about certified labs?
Please click on the Certified centres and Certification Round sections on the website.

When will the samples be sent?
You will be informed via email.

How many samples will be sent?
You will receive five samples.

Which type of samples will be sent?
DNA samples.

Which techniques are being certified?
Next Generation Sequencing and Sanger Sequencing.

Can my lab certify for more than one technique?
Yes.